 | |
| Clinical data | |
|---|---|
| Trade names | Mexitil, NaMuscla, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607064 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 90% |
| Protein binding | 50–60% |
| Metabolism | Liver (CYP2D6 and 1A2-mediated) |
| Onset of action | Within 2 hr[1] |
| Elimination half-life | 10–12 hours |
| Excretion | Kidney (10%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H17NO |
| Molar mass | 179.263 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Mexiletine, sold under the brand name Mexitil among others, is a medication used to treat ventricular arrhythmias that are life threatening and certain types of myotonia.[1][2] It may be used when other treatments do not work.[1] While it has been used for diabetic neuropathy such use is not well supported.[1] It is taken by mouth.[1]
Common side effects include chest discomfort, headache, lightheadedness, and nausea.[1] Other side effects may include arrhythmias, heart failure, liver problems, low platelets, seizures, and low white blood cells.[1] It is a class IB anti-arrhythmic and works as a sodium channel blocker.[1][2]
Mexiletine was approved for medical use in 1985.[1] It is available as a generic medication.[3] In the United Kingdom 100 pills of 167 mg costs the NHS about £5,000 as of 2021.[2] In the United States 100 pills of 150 mg costs about 47 USD.[3]
References edit
- ^ a b c d e f g h i j k l "Mexiletine Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 18 November 2021.
- ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1172. ISBN 978-0857114105.
- ^ a b "Mexiletine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 18 November 2021.